Frag' FlorenceEvidenz. Klar. Anwendbar.
Uhr 7/8Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

10.3389/fpsyg.2012.00132

CrossRef Listing of Deleted DOIs · 2000

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Photodynamic priming (PDP), a fallout of photodynamic therapy, transiently modulates the tumor microenvironment (TME), enhances therapeutic susceptibility, and promotes immunogenic cell death through the release of damage-associated molecular patterns (DAMPs). Pancreatic ductal adenocarcinoma (PDAC) remains non-responsive to current therapies with a desmoplastic and immunosuppressive TME that limits drug delivery and blunts responses to immune checkpoint blockade. We investigated whether PDP could enhance anti-PD1 therapy responses in PDAC using patient-derived organoids (PDOs). PDOs were treated with Visudyne and red light (25, 75, and 100 J/cm²), followed by assessment of cytotoxicity, DAMP expression (HSP60, calreticulin, HMGB1), and transcriptomic changes. Monocyte-derived dendritic cells (mDCs) from healthy donors were cocultured with PDP-treated (25 J/cm 2 ) PDOs, then with matched naïve T cells. mDC and T cell activation markers were analyzed. Pembrolizumab (anti-PD1) was added to PDO-mDC-T cell cocultures to evaluate combined effects on PDO viability and T cell activation. PDP induced dose-dependent cytotoxicity and upregulated DAMPs. Gene profiling in PDOs showed increased <i>IFN-γ</i>, <i>TNF-α</i>, and <i>CXCL12</i>, with reduced <i>PD-L1</i>, <i>TGF-β1</i>, and <i>FOXP1</i> expression. mDCs exposed to PDP-treated PDOs upregulated CD40, CD86, and MHC-II, driving activation of CD4 + and CD8 + T cells, evidenced by elevated PD1 expression. Addition of pembrolizumab further decreased PDO viability and amplified effector cytokines (<i>IFN-γ</i>, <i>TNF-α</i>, <i>FASLG</i>, <i>granzyme</i> B, <i>IL-2</i>, <i>IL-21</i>). PDP was associated with modulation of the PDAC TME toward a more immunogenic phenotype by enhancing tumor immunogenicity, activating dendritic cells and T cells, and potentiating PD1 blockade. These findings provide mechanistic support for further preclinical and clinical evaluation of PDP combined with checkpoint inhibition in PDAC.

Abstract: PubMed · Datensatz

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Nicht angegeben
Quelle
CrossRef Listing of Deleted DOIs
Publikation
2000-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
0849-6757
Zitationen
14 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

(2000). 10.3389/fpsyg.2012.00132. CrossRef Listing of Deleted DOIs. https://doi.org/10.3389/fimmu.2026.1805948
RIS BibTeX CSL-JSON